Targeted Cancer Panel (CCGSv3.2)
Tests are performed using targeted hybridization capture of tumor-derived genomic DNA coupled with next-generation sequencing (NGS). This approach enables deep, comprehensive coverage of all coding exons and key introns of ordered genes, and allows assessment of the molecular complexity of each DNA specimen, minimizing sampling bias even in cases of low DNA mass or quality.
Types of variation detected include single nucleotide variants (SNVs), small insertions and deletions (indels), selected larger indels, and structural rearrangements involving selected genes.
For solid tumors, this test is routinely performed using formalin fixed paraffin embedded (FFPE) tissues and is able to detect SNVs under 10% allelic fraction in the sequenced tissue.